Community-based cardiovascular Risk Factors Intervention Strategies (CORFIS) in managing hypertension: A pragmatic non-randomised controlled trial by Low, W.H.H. et al.
Med J Malaysia Vol 68 No 2 April 2013 129
SUMMARY
Background: Hypertension is the number one
cardiovascular risk factor in Malaysia. This study aimed to
evaluate the effectiveness of a Community-Based
Cardiovascular Risk Factors Intervention Strategies
(CORFIS) in the management of hypertension in primary
care. 
Methods: This is a pragmatic, non-randomized controlled
trial. Seventy general practitioners (GPs) were selected to
provide either CORFIS (44 GPs) or conventional care (26
GPs) for 6 months. A total of 486 hypertensive patients were
recruited; 309 were in the intervention and 177 in the control
groups. Primary outcome was the proportion of
hypertensive patients who achieved target blood pressure
(BP) of <140/90mmHg (for those without diabetes mellitus)
and <130/80mmHg (with diabetes mellitus). Secondary
outcomes include change in the mean/median BP at 6-month
as compared to baseline.
Results: The proportion of hypertensive patients who
achieved target BP at 6-month was significantly higher in the
CORFIS arm (69.6%) as compared to the control arm (57.6%),
P=0.008. Amongst those who had uncontrolled BP at
baseline, the proportion who achieved target BP at 6-month
was also significantly higher in the CORFIS arm (56.6%) as
compared to the control arm (34.1%), p<0.001. There was no
difference in the patients who had already achieved BP
control at baseline. There were significant reductions in SBP
in the CORFIS arm (median -9.0mmHg; -60 to 50) versus
control (median -2mmHg; -50 to 48), p=0.003; as well as in
DBP (CORFIS arm: median -6.0mmHg; ranged from -53 to 30
versus control arm: median 0.0mmHg; ranged from -42 to
30), p<0.001. 
Conclusions: Patients who received CORFIS care
demonstrated significant improvements in achieving target
BP.
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INTRODUCTION
Prevalence of chronic diseases is rising at an alarming rate
globally. It is estimated that 46% of global disease burden is
attributed to chronic diseases and this figure is expected  to
reach  60% by the year 2020 1. The 2006 National Health and
Morbidity Survey (NHMS) in Malaysia showed that the
prevalence of hypertension is 32.2% and this makes
hypertension the commonest chronic disease in Malaysia.
Findings from 2006 NHMS showed that only 33% of patients
diagnosed to have hypertension were aware of the diagnosis
and among them, only 23% were on treatment.  Among
those on treatment, only 26% achieved target blood pressure
(BP) control 2. The proportion of patient achieving good
control of BP was lower than that observed in the 1996
NHMS3. These findings, together with the high prevalence of
other cardiovascular risk factors such as hyperlipidaemia,
obesity and smoking, contribute to the increasing burden of
cardiovascular morbidity and mortality in Malaysia 4.
Studies have shown that patients who received
antihypertensive treatment at primary care clinics and
private general practitioners had sub-optimal management
and poor outcomes 5,6.  It has also been noted that private
general practitioners in Malaysia often work in solo practice
without allied health support from pharmacists and
dietitians 7. On the other hand, though public primary care
clinics have access to pharmacists and dietitians, the
multidisciplinary approach to patient care is not the norm
due to patient load and time constraints.  
Effective management of chronic diseases requires focus on
the needs of the patients as opposed to the traditional
primary care delivery model which provides only acute
episodic care. The Chronic Care Model (CCM) developed by
Wagner et al 8,9 which was later adapted by the World Health
Organisation (WHO) 1,10, is an evidence-based framework for
chronic disease management. Optimal chronic care is
achieved when a well-coordinated, proactive healthcare
team interacts productively with an informed and motivated
patient. The CCM has greatly influenced the reorganisation
of chronic disease care in many developed countries 11-13.
However, evidence is still lacking to show if such CCM is
feasible or is effective in developing countries.  
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Therefore, this study was conducted to evaluate the
effectiveness of a Community-Based Cardiovascular Risk
Factors Intervention Strategies (CORFIS), which was designed
based on  the CCM, in managing patients with  hypertension
in the private primary care settings in Malaysia. 
MATERIALS AND METHODS
This was a pragmatic, non-randomized multi-centre
controlled trial. Blinding was not possible due to the nature
and complexity of the intervention. This study was approved
by the Medical Research Ethics Committee of the Ministry of
Health Malaysia (MOH) and was conducted in accordance
with the Declaration of Helsinki and Good Clinical Practice
(GCP) requirements. All participants gave their written
informed consent. This study was registered with clinical
trial.gov and reporting was done in accordance to the
CONSORT Statement 2010 14, 15. 
Study sites
Seventy General Practitioners (GPs) who were registered in
the National Medical Health Directory from the state of
Selangor and Kuala Lumpur were invited to participate. They
were allocated to either the intervention or control group in a
2 to 1 ratio.
Study population
The GPs recruited patients who attended their clinics between
January to June 2008 according to the inclusion and
exclusion criteria. The inclusion criteria were patients aged >
18 years, were diagnosed with hypertension with or without
diabetes mellitus or hyperlipidaemia, and were currently on
at least one medication for one or more of these conditions.
Women who were pregnant or were breast feeding, patients
who had history of unstable angina, acute myocardial
infarction, heart failure, clinically significant valvular heart
disease, stroke or who had serum creatinine of more than
150umol/L in the preceding 6 months, and who had
coronary revascularisation procedure were excluded.
Study intervention
The study intervention, referred to as the CORFIS programme,
was developed in accordance with the Medical Research
Council (MRC) guidance on developing and evaluating
complex interventions to improve health outcomes 16. The
underlying framework in developing the complex
intervention for CORFIS was based on 5 out of the 6
interrelated elements of the CCM 8,9 as described below:
1. Delivery system re-design – Allied health care team
consisting of a pharmacist, dietitian and nurse educator
was constituted purposefully to support individual GPs.
They provided patient education and counselling as well
as taught patients on self-monitoring. Tele-monitoring
services, provided by trained nurse advisors helped to
reinforce self-care, monitor treatment adherence and
provide necessary care support. The team undertook
regular assessment tailored to the needs of individual
patients, which formed the basis of a mutually agreed care
plan including regular follow-up visits to the GPs and
other members of the team.
2. Decision support - Each team member delivered care
according to an agreed management and drug treatment
protocol which was developed based on local clinical
practice guidelines (CPGs) for hypertension 17, published by
the MOH.  Medical nutrition therapy was advocated for
patients by dietitians according to a clinical protocol based
on evidence-based practice guidelines for hypertension.
Selected clinical specialist advisors consisting of general
physicians, endocrinologists, cardiologists,
ophthalmologists and nephrologists provided remote
disease organ screening review (retinopathy, cardiac
diseases and nephropathy) as well as feedback to
participating GPs on therapeutic decision making or
treatment modification for individual patients via the
online clinical information system.
3. Clinical Information System - A custom designed, secure
web-based application was set-up to capture patients’ data
as well as to organise and coordinate care among all the
healthcare providers. This included electronic laboratory
result transmission and project management. The system
also provided reminders to prompt both the providers and
patients on specific actions to be taken such as clinical
visit appointment, blood sampling and home monitoring.
Patients were able to access their personal medical records,
educational materials, local support link and recording of
self-monitored BP (SMBP), self-monitored random blood
glucose (SMBG) and pedometer readings through a secure
web-based portal at www.corfis.gov.my
4. Patient empowerment and self-management support –
Individualised patient-centred care was enforced
throughout the study. The trained allied health
professionals counselled the patient monthly at their
assigned GP clinics. Continuity of care for patient by the
same care-provider was emphasised to establish positive
rapport between the patients and the healthcare team
members. Home monitoring devices such as digital
automatic BP monitors (OMRON IA2), home blood glucose
monitors (ABBOTT Optium Exeed) and pedometers (OMRON
HJ-113) were loaned to the patients for the duration of the
study. 
5. Community Resources - Patients were provided with
information on local patient associations and support
groups with the aim of fostering mutual support and
motivation of self-care. Focus group sessions were
conducted to facilitate discussion.
Conduct of study
The intervention was delivered over a period of 6 months.
Visits by the allied health team occurred within 30 days after
the initial recruitment and baseline investigations [such as
HbA1c, fasting blood sugar (FBS), serum lipid profile, serum
creatinine, blood chemistry and urinalysis] and then at
monthly interval thereafter for 6 months. Thus, all patients
in the intervention arm were required to attend at least 3
visits including the 6-month follow-up. Those who did not
comply with this schedule were considered as lost to follow-
up. There was no limit to the number of GP visits a patient
was allowed to make in either arm during the course of the
study. 
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Table I: Baseline characteristics of hypertensive patients allocated to the intervention and control arms.
Characteristics Intervention Control P value
N = 309 N = 177
Age, years; Mean (SD) 49 (9) 52 (10) 0.0044
Gender; n (%) Male 197 (64) 97 (55)
Female 112 (36) 80 (45)
Ethnic Group; Malay 136 (44) 84 (47) 0.0061
n (%) Chinese 98 (32) 70 (40)
Indian 66 (21) 22 (12)
Other 9 (3) 1 (1)
Education Attainment; Primary 18 (6) 36 (20) <0.0011
n (%) Secondary 145 (47) 94 (53)
Tertiary 111 (36) 38 (22)
Nil / Missing 35 (11) 9 (5)
Occupation; n (%) Legislator senior officials 21 (7) 10 (6) <0.0011
Technicians, associate professionals 33 (11) 16 (9)
Service worker, shops & market sales workers 26 (9) 16 (9)
Craft & Related Trades Workers 7 (2) 3 (2)
Elementary occupations 12 (4) 6 (3)
Professionals 50 (16) 14 (8)
Clerical workers 38 (12) 16 (9)
Skilled agricultural, fishery workers 1 (0) 0 (0)
Plant & machine operators assemblers 4 (1) 13 (7)
Others / Missing 117 (38) 83 (47)
Cardiovascular Comorbidities; HPT only 77 (25) 57 (32)
n (%) HPT + DM 52 (17) 29 (16)
HPT + HLP 85 (28) 47 (27)
HPT + DM + HLP 95 (30) 44 (25)
Tobacco use; n (%) Never use 214 (69) 142 (80) 0.0051
Former (quit >30 days) 32 (10) 10 (6)
Current use (any tobacco use within last 30 days) 44 (14) 23 (13)
Unknown / Missing 19 (7) 2(1)
Family history; Hypertension 208 (67) 118 (67)
n (%) Diabetes Mellitus 149 (48) 81 (46)
Hyperlipidaemia 74 (24) 20 (11)
*Cumulative CVD risk 0–1 risk factor for CVD 52 (17) 39 (22)
factors; n (%) ≥ 2 risk factors for CVD 110 (36) 64 (36)
Presence of coronary artery disease or diabetes 147 (47) 74 (42)
Sitting Systolic Blood Mean (SD) 135 (16) 136 (18)
Pressure (SBP); mmHg Median (min, max) 134 (92,196) 130 (110,210)
Sitting Diastolic Blood Mean (SD) 84 (10) 85 (11)
Pressure (DBP); mmHg Median (min, max) 85 (58,118) 82 (58,130)
Standing Systolic Blood Mean (SD) 136 (16) 137 (18)
Pressure (SBP); mmHg Median (min, max) 134 (98,195) 134 (106,220)
Standing Diastolic Blood Mean (SD) 88 (10) 88 (11)
Pressure (DBP); mmHg Median (min, max) 90 (37,123) 88 (65,130)
BMI; kg/m2 Mean (SD) 29 (6) 29 (5)
Median (min, max) 28 (15,65) 28 (19,54)
Waist circumference (WC); cm Mean (SD) 95 (12) 94 (11)
Median (min, max) 95 (35,140) 93 (68,126)
Total Cholesterol; mmol/L Mean (SD) 5.2 (1.0) 5.4 (1.1)
Median (min, max) 5.2 (2.4,8.6) 5.4 (3.0,8.9)
HDL; mmol/L Mean (SD) 1.2 (0.3) 1.2 (0.3)
Median (min, max) 1.2 (0.7,2.3) 1.2 (0.8,2.0)
LDL; mmol/L Mean (SD) 3.2 (0.9) 3.3 (1.0)
Median (min, max) 3.2 (0.7,6.5) 3.3 (1.3,6.5)
Triglyceride; mmol/L Mean (SD) 1.8 (1.1) 1.9 (1.1)
Median (min, max) 1.5 (0.4,9.5) 1.6 (0.4,7.4)
Total Cholesterol/HDL Ratio Mean (SD) 4.3 (1.0) 4.5 (1.2)
Median (min, max) 4.2 (1.9,7.5) 4.4 (2.1,8.5)
Fasting Blood Glucose; mmol/L Mean (SD) 6.4 (2.5) 6.6 (3.1)
Median (min, max) 5.6 (3.7,21.4) 5.5 (3.1,23.7)
HbA1C; % Mean (SD) 6.9 (1.8) 6.9 (1.7)
Median (min, max) 6.3 (4.1,13.6) 6.2 (4.7,13.0)
Abbreviation: SD = standard deviation; HPT = hypertension; DM = diabetes mellitus; HLP = hyperlipidaemia; CV = cardiovascular; CAD = coronary artery
diseases; BMI = body mass index; TC = total cholesterol; HDL = high density lipoprotein; LDL = low density lipoprotein; HbA1C = glycosylated haemoglobin. 
* Risk factors are defined as dyslipidaemia, hypertension, diabetes, smoking, family history of premature cardiovascular disease and obesity
1 denotes Pearson chi-square test
4 denotes Independent t-test
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Outcome Measures
The primary outcome was defined as the proportion of
patients who achieved target BP after 6 months. Target BP for
patients without diabetes mellitus (DM) was ≤140/90 mmHg
and with DM was ≤130/80 mmHg 18. 
Secondary outcomes were changes in the mean/median BP at
the end of the study as compared to baseline. 
Sample Size Calculation
Sample size was calculated based on the proportion of
patients with hypertension who had good control, that is
BP<140/90 mmHg, based on the NHMS 2006 results, which
was 27% 4.  The outcome target for  this study was set at 1.5
times higher than 27%. By using a two group χ2 test of equal
proportion, type I error of 0.05 and 80% power of detection,
290 patients were required for the intervention group and
145 patients for the control group (2:1 ratio). Adding a 15%
drop out rate, the total sample size should be 500. 
Statistical Analysis
All data were analysed using the Statistical Package for Social
Sciences (SPSS Inc., Chicago, IL, USA), version 16. Continuous
variables were described using summary statistics such as
mean, median, standard deviation, maximum and
minimum values. Categorical (nominal/ordinal) variables
were described using frequencies and percentages.  Chi
square test was used to assess effectiveness of the intervention
using the difference in the proportion of patients who
achieved BP target. Multivariate logistic regression analysis
was used to measure the effect of confounders. A p-value of
less than 0.05 was considered as statistically significant.
The intention to treat analysis was conducted. Participants
with missing data at 6-month follow-up had their data
imputed by method of Last Observation Carried Forward
(LOCF). 
RESULTS
Seventy GPs participated in the study. Forty four GPs were
allocated to the intervention group and 26 GPs to the control
group. The participating GPs recruited 486 patients with
hypertension, 309 were in the intervention group and 177
were in the control arm. However, 275 in the intervention
and 149 in the control group completed the study. (Figure 1)
Table I shows the baseline characteristics of the study
participants. Age, ethnicity, education attainment,
occupation and smoking status were significantly different
between the two groups.
Table II shows the primary outcome at 6-month follow-up.
The proportion of participants with hypertension who
achieved target BP was significantly higher in the
intervention group (69.6%) as compared to the control group
(57.6%) (p<0.008). Amongst those who had uncontrolled BP
at baseline, the proportion who achieved target BP at 6-
month was also significantly higher in the intervention
group (56.6%) as compared to the control group (34.1%)
(p<0.001). There was no significant difference in the
achievement of target BP at 6-month among patients who
had already achieved BP control at baseline. 
Table III shows the overall change in median systolic and
diastolic BP (SBP and DBP) after 6 months. There were
significant reductions in SBP in the intervention group.
Table II: Primary outcome: proportion of hypertensive patients who achieved target blood pressure at 6-month follow-up
Variables Intervention; n=309 Control; n=177 Crude OR (95% CI) p-value
n (%) n (%)
Hypertensive patients with
• Uncontrolled BP at baseline 159 (51.5) 88 (49.7) 0.93 (0.64 – 1.35) 0.7841
• Controlled BP at baseline* 150 (48.5) 89 (50.3)
Total hypertensive patients who achieved 215 (69.6) 102 (57.6) 1.68 (1.15 – 2.47) 0.0082
target BP at 6-month
Hypertensive patients with uncontrolled 90 (56.6) 30 (34.1) 2.52 (1.47 – 4.33) <0.0012
BP at baseline who achieved target BP 
at 6-month
Hypertensive patients with controlled 125 (83.3) 72 (80.9) 1.18 (0.59 – 2.33) 0.6632
BP at baseline maintain target BP at 6-month
1 denotes Fisher’s exact test
2 denotes Pearson chi-square test
* Blood pressure control is defined as BP of <140/90mmHg (for those without diabetes mellitus) and <130/80mmHg (for those with diabetes mellitus).
Table III: Secondary outcome: change in the mean blood pressure at 6-month as compared to baseline
Variables Intervention; Control; p-value
n=309 n=177
SBP at baseline; Median (IQR) 134 (92 to 196) 130 (110 to 210) 0.7023
DBP at baseline; Median (IQR) 85 (58 to 118) 82 (58 to 130) 0.9063
SBP at 6-month; Median (IQR) 128 (87 to 181) 130 (98 to 193) <0.0013
DBP at 6-month; Median (IQR) 80 (52 to 111) 83 (51 to 120) <0.0013
Change in SBP at 6-month from baseline; Median (IQR) -9 (-60 to 50) -2 (-50 to 48) 0.0033
Change in DBP at 6-month from baseline; Median (IQR) -6 (-53 to 30) 0 (-42 to 30) <0.0013
3 denotes Mann Whitney U test
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There was no difference in the mean number of
antihypertensive agents prescribed in both groups. However,
there were differences in the types of antihypertensive agents
prescribed by the GPs in the intervention group compared to
the control group. In the intervention group, angiotensin
receptor blockers (ARBs) was the most popular choice (43%),
followed by angiotensin converting enzyme inhibitors
(ACEIs), diuretics and calcium channel antagonists (CCAs).
In the control arm, 59% of antihypertensive agents
prescribed were thiazide diuretics, followed by ACEIs, beta-
blockers, ARBs and CCAs. GPs in both groups did not change
their drug prescribing pattern during the 6 months of the
study period but the volume of prescriptions increased in
both groups. 
A multivariate logistic regression analysis was conducted to
analyse the potential confounding factors identified at
baseline between the intervention and control groups. These
include age of participants, ethnicity, education attainment,
occupation and smoking status. Apart from participants who
were smokers, none of the factors identified had an effect on
achieving the target BP. Based on the analysis, hypertensive
patients  who were active smokers would benefit less from the
CORFIS intervention(OR=0.39, 95% CI 0.19-0.82, p=0.012).
No adverse events were reported throughout the study. 
DISCUSSION
The CCM represents an evidence-based conceptual
framework for improved patient care and clinical outcomes
as shown by several systematic reviews 19-21. This study
provided evidence that chronic disease management strategy
based on the CCM is effective in improving BP control.  The
proportion of participants who achieved BP target in the
CORFIS group was significantly higher compared to the
control group. This is particularly so among participants who
had uncontrolled BP at baseline. Significant reductions in
both SBP and DBP were also observed in the CORFIS group
compared to the control group. The improvement in clinical
outcomes seen in the CORFIS group were not affected by
confounding factors such as age, ethnicity, education
attainment and occupation of the participants.  These
improvements were more likely to be attributed to the CORFIS
intervention.  However, hypertensive patients who were
active smokers would benefit less from the CORFIS
intervention.
Fig. 1 : CORFIS Trial Profile: Enrolment of GP practices and recruitment of hypertensive patients.
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Evidence to support the elements of the CCM used to design
the CORFIS programme is robust. Multidisciplinary primary
care team plays a pivotal role in improving the clinical
outcomes, given the complexity of managing chronic
conditions 22-24. Studies using nurse-led or pharmacist-led
multidisciplinary interventions revealed significant
improvement in the process of care and BP control 25-27. The
multidisciplinary team members in the CORFIS arm were
trained in patient-centred communication and counselling
skills to empower the patients to self-manage. There is
enough evidence to show that patient-centred counselling,
behavioural interventions and self-management support
improved BP control compared to usual care, beyond the
benefits afforded by medications alone 28-30. 
An organized clinical information system of registration,
recall and regular review appeared to be the most effective in
improving BP control 31. In the CORFIS study, a custom
designed web-based application was used to organise
patients’ data and coordinate care among all the healthcare
providers. As for decision support, integration of locally
relevant evidence-based CPGs into the fabric of patient care
is fundamental to putting evidence into practice in
managing chronic diseases 32. Vigorous stepped care
approach to antihypertensive drug treatment has been
shown to improve outcomes 31. In the CORFIS study, team
members were trained to utilise a stepped care protocol
developed based on the local CPGs.  GPs from the
intervention arm were found to be more likely to adhere to
the CPGs as demonstrated by the higher usage of ACEIs and
ARBs as primary treatment choice compared to beta-blockers
and thiazide diuretics in the control group. Recent evidence
suggested that adherence to evidence-based prescribing
guidelines for hypertension resulted in substantial savings in
prescription costs 33. Joint participation and enhancing
information exchange between primary care and secondary
care physicians in a planned delivery of care has been shown
to improve management of chronic diseases and lead to
better outcomes 34. In the CORFIS arm, the GPs were supported
by a group of clinical specialist advisors in managing difficult
cases. Evidence has also shown that building collaborative
network with the community resources helped to address
complex health issues in chronic disease care 35. The CORFIS
study incorporated the community collaboration by
conducting focus support group sessions to foster mutual
support and motivation for self-care.
Limitations of the Study
The CORFIS study has provided valuable insights on the
limitations and constraints of conducting a pragmatic
controlled trial in primary care in Malaysia. This includes the
infeasibility of randomising the GP clinics due to
geographical distance and shortage of allied health support
team. Blinding was also not possible as in most of the other
complex intervention trials. The short duration of this study
posed an important question on whether the significant
improvement in BP outcomes was sustainable over a longer
period of care. 
Given the limitations and the current constraints faced by the
private GPs, the results of this study are encouraging.  In
reality, challenges to provide high quality chronic disease
care based on the CCM in the private GPs is common 36.
Substantial investments would be required by most of the GPs
to implement those changes and to expend the necessary
resources which are not conducive in the current payment
mechanism. Without government funding, it would be too
expensive for the GPs to employ allied health team to support
chronic disease care. Often, comprehensive chronic disease
care packages are not covered by private health insurance
companies.  In the absence of universal funding scheme, it is
often too expensive for patients with multiple chronic
conditions to bear the out-of-pocket payment to the GPs. As a
result, the over-subsidised public primary care sector is
overburdened to provide care to the majority of patients with
chronic conditions.
The rising epidemic of chronic diseases puts the private
general practice in demand to play a greater role in chronic
disease management. Therefore, the results of this study
should offer potential to leverage significant policy change
towards a more integrated healthcare system supported by a
universal funding mechanism. The recently announced
proposal by the Malaysian government to set up a social
health insurance scheme which will integrate the private and
public primary care services under a common network of
care37, offers a potential solution for the private GPs to work
in collaboration with other healthcare providers in
improving the delivery system for chronic diseases.
CONCLUSION
In conclusion, this is a landmark study in Malaysia that has
proven that patients who received multifaceted chronic care
intervention demonstrated significant improvements in the
clinical outcomes.  Further research to evaluate the cost-
effectiveness of this intervention and the sustainability of the
improved outcomes over long term should be conducted.
There is also a need to evaluate the effectiveness of this
intervention in the public primary care setting where a larger
proportion of patients with chronic conditions are receiving
care.
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